Global Prader-Willi Syndrome Market - 2022-2029

Global Prader-Willi Syndrome Market - 2022-2029

Market Overview

Prader-Willi syndrome market is expected to grow at a CAGR of 4.5% in the forecast period (2022-2029).

Prader-Willi syndrome (PWS) is a genetic disorder due to the deletion of a part of the father's chromosome 15. Prader-Willi syndrome can also be due to the presence of two copies of chromosome 15 inherited by the mother only, leading to their suppression during gene formation. PWS therapeutics have a wide scope in the global market, as no known cure is available for such a complex genetic disorder.

Market Dynamics

The major driving forces are increasing the number of special drug designations from regulatory bodies, an increasing number of the diagnosed patient population, growing human growth hormone therapy coverage rate, a strong pipeline, growing strategic alliances, use of advanced technologies for the diagnosis and treatment of PWS, and surging awareness.

The ongoing research on treating Prader-Willi syndrome is pushing the market’s growth.

The ongoing studies for treating Prader-Willi syndrome are fueling the global market growth. For instance, according to Clinical Trials.gov currently, 3 studies are active; namely, a study sponsored by Harmony Biosciences, LLC titled a randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and the efficacy of Pitolisant in patients with Prader-Willi syndrome, followed by an open-label extension, which is estimated to complete by October 2022, a phase 3 multicenter, open-label, multi-cohort study for evaluation of the efficacy and safety of somatropin in Japanese participants with Prader-Willi syndrome (PWS) study sponsored by Pfizer, with the estimated completion on May 25, 2024, and an open-label, long-term safety evaluation of diazoxide choline controlled-release tablet in patients with Prader-Willi syndrome sponsored by Soleno Therapeutics, Inc. with estimated completion on June 2023. Furthermore, 12 more studies on different interventions for Prader-Willi syndrome are currently recruiting, driving the global market growth.

The lack of awareness and limited treatment efficiency slows the Prader-Willi syndrome (PWS) market growth.

However, the limited efficacy of the current therapies, lack of awareness of the Prader-Willi syndrome, and the presence of complications associated with the diseases are expected to restrain the market growth.

Prader-Willi syndrome (PWS) Market-Industry analysis.

The Prader-Willi syndrome (PWS) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis, Etc.

COVID-19 Impact Analysis

COVID-19 is an atypical health concern that has profoundly impacted the global Prader-Willi syndrome (PWS) market growth. In the course of the outbreak, restrictions were imposed by different regulatory bodies for controlling the spread of the infection regarding the socializing of people, which made it difficult to get regular healthcare check-ups on time leaving many cases of Prader-Willi syndrome (PWS) undetected. Moreover, the restrictions on transportation affected the import and export, affecting the supply chain of many market players, overall reducing the availability of Prader-Willi syndrome (PWS) in the market, reducing sales, and negatively impacting the market growth globally.

Segment Analysis/B>

The recombinant growth hormone treatment for Prader-Willi syndrome (PWS) is estimated to oppress the market during the forecast period (2022-2029).

The recombinant growth hormones segment is expected to grow rapidly over the forecast period (2022-2029). Currently, the pharmacological management of Prader-Willi syndrome (PWS) focuses mainly on using human growth hormone (HGH) supplementation, which is approved in the US. Growth hormone(GH) supplementation constitutes the primary component of the entire therapeutic market composition due to the nearly ubiquitous deficiency of growth hormone (GH) in PWS patients. Some majorly approved GH therapies include Pfizer's Genotropin (somatropin), other major brands such as Norditropin (Novo Nordisk), and others in the US. Another approved drug is Omnitrope (somatropin [rDNA origin] injection) from Sandoz. Also, ongoing clinical trials on growth hormones are expected to boost the market growth. For instance, a study sponsored by OPKO Health, Inc. on safety and dose-finding study of different MOD-4023 dose levels compared to daily R-human Growth Hormone (hGH) therapy in pre-pubertal growth hormone deficient children is estimated to complete on December 12, 2024, another phase 3, open-label, randomized, multicenter, 12 months, study on the efficacy and the safety of weekly MOD-4023 compared to daily Genotropin - therapy in pre-pubertal children with growth hormone deficiency sponsored by OPKO Health, Inc. and estimated completion is in December 2022.

Geographical Analysis

North America is predicted to hold most of the market share.

North America oppressed the global Prader-Willi syndrome market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing prevalence of Prader-Willi syndrome in the region and a growing number of ongoing research and development activities on the Prader-Willi syndrome. For instance, according to the National Institute of Health, the number of individuals with Prader Willi Syndrome is approximately 400000, and 20000 of these cases are in the United States. The presence of organizations creating awareness about PWS in the region is also expected to drive market growth. For instance, the Prader-Willi Syndrome Association (USA) has provided life-saving research, crisis, family support, medical and new parent support since 1975 and The Foundation for Prader-Willi Research, a non-profit corporation established in 2003. Furthermore, the presence of highly advanced and robust healthcare infrastructures in North America contributes to its dominance over the global Prader-Willi syndrome market.

Competitive Landscape

The key players operating in the global Prader-Willi syndrome market are Novartis, Soleno Therapeutics, Saniona, Pfizer, Millendo Therapeutics, Inc., Levo Therapeutics, Inc., Rhythm Pharmaceuticals, Essentialis, Inc., LG Corp and Novo Nordisk. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Prader-Willi syndrome market globally. For instance, on Aug 25, 2022, Novartis announced to spin off the Sandoz business creating a standalone company. Also, on July 20, 2022, FDA acknowledged that data from a randomized withdrawal period of Study C602 by Soleno Therapeutics have the potential to support an NDA submission.

Pfizer Inc.

Overview

Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.

Product Portfolio

Pfizer`s Prader-Willi syndrome (PWS) product portfolio has Genotropin and NGENLA.

The Prader-Willi syndrome (PWS) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.